CTA gene of interest No. of samples tested Matched normal tissue tested? % Expression in cell lines
(number of positive cell line expression/number of cell lines tested)
Comments
ADAM-2 29 [94,114] No   ADAM-2 also referred to as CT15
CT9 6 [139] No   CT9 referred to as bromodomain testis-specific gene (BRDT)
CT17 9 [114] No    
CT47 6 [140] No (3/3) 100% [140] Not certain from text if CT47 expression detected in all three cell lines.  Quantitative PCR and relative expression to testis used to decide if not expressed in tumour tissue.
FTHL17 11 [90] No    
GAGE-1 to GAGE-8 34 [55] Yes   Eight GAGE family members tested (i.e. GAGE-1-8)
KU-CT-1 21 [72] No (0/7) 0% [72] Note: 1 out of 18 patients (5.6%) had a positive serological test
MORC 20 [94] No    
MMA-1A 5 [141] No (1/8) 12.5% [141] Weak expression in cell lines only
MMA-1B 5 [141] No (2/8) 25% [141] Weak expression in cell lines only
PAGE-1 34 [55] Yes    
RAGE-4 34 [55] Yes    
SAGE 19 [119] No    
SCAGE-ac 34 [55] Yes    
SGY-1 20 [94] No    
SPO11 20 [94] No    
TAF2Q 11 [90] No    
TDRD1 8 [90] No    
TEX15 8 [90] No   Expressed in normal brain tissue
TPX-1 20 [94] No    
Table 2: Well characterised CTA genes that have no evidence of expression in CRC tissue.